C-reactive protein: How conformational changes influence inflammatory properties

Recent evidence suggests that the prototypic acute phase reactant C-reactive protein (CRP) is not only a marker but also a potential contributor to inflammatory diseases. CRP belongs to the family of pentraxins and as such consists of five identical non-covalently linked subunits. Contradictory data on the characteristics of CRP as either being pro- or anti-inflammatory may be explained by the existence of two conformations of the protein: the circulating native, pentameric CRP (pCRP) and the monomeric isoform (mCRP), formed as a result of a dissociation process of pCRP. In vitro both isoforms exhibit a very distinct inflammatory profile. We recently identified a localized, physiologically relevant pCRP dissociation mechanism by activated platelets and apoptotic cells and showed the deposition of mCRP in inflamed tissue. Here we review the literature on the causal role of p- and mCRP in the light of our findings and critically analyze the current controversies around CRP. The novel understanding of the localized dissociation of circulating pentameric CRP to the distinctively pro-inflammatory monomeric CRP allows for a new view on CRP in inflammatory reactions and further highlights mCRP and the pCRP dissociation process as a potential therapeutic target.

[1]  A. Agrawal,et al.  Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[2]  A. Murphy,et al.  Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques , 2009, Circulation research.

[3]  J. Filep,et al.  Monomeric C‐reactive protein activates endothelial cells via interaction with lipid raft microdomains , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  J. Danesh,et al.  C‐reactive protein and coronary heart disease: a critical review , 2008, Journal of internal medicine.

[5]  K. Matthews,et al.  Ethnic differences in C-reactive protein concentrations. , 2008, Clinical chemistry.

[6]  Claudio J. Verzilli,et al.  Bayesian meta-analysis of genetic association studies with different sets of markers. , 2008, American journal of human genetics.

[7]  K. Peter,et al.  Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules , 2007, Nature Protocols.

[8]  J. Tegnér,et al.  Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia , 2007, Proceedings of the National Academy of Sciences.

[9]  L. Lerman,et al.  Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans , 2007, Circulation.

[10]  C. Bode,et al.  Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents. , 2007, Blood.

[11]  W. Lu,et al.  Cell membranes and liposomes dissociate C‐reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  M. Criqui,et al.  Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. , 2006, American heart journal.

[13]  S. Simon,et al.  CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. , 2006, American journal of physiology. Heart and circulatory physiology.

[14]  Steven V. Ley,et al.  Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.

[15]  Paul M Ridker,et al.  C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. , 2006, Journal of the American College of Cardiology.

[16]  M. Sabatine,et al.  Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial , 2006, Circulation.

[17]  J. Zhao,et al.  Effect of Modified C-Reactive Protein on Complement Activation: A Possible Complement Regulatory Role of Modified or Monomeric C-Reactive Protein in Atherosclerotic Lesions , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[18]  R. Wander,et al.  Production of Modified C-Reactive Protein in U937-Derived Macrophages , 2005, Experimental biology and medicine.

[19]  J. Filep,et al.  Loss of pentameric symmetry of C‐reactive protein induces interleukin‐8 production through peroxynitrite signaling in human neutrophils , 2005, Circulation research.

[20]  E. Yeh,et al.  Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. , 2005, Journal of the American College of Cardiology.

[21]  C. Wanner,et al.  Native C-Reactive Protein Increases Whereas Modified C-Reactive Protein Reduces Atherosclerosis in Apolipoprotein E–Knockout Mice , 2005, Circulation.

[22]  J. Jukema,et al.  No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[23]  M. Blettner,et al.  Role of C-Reactive Protein in Atherogenesis: Can the Apolipoprotein E Knockout Mouse Provide the Answer? , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Arjun Deb,et al.  Proapoptotic, Antimigratory, Antiproliferative, and Antiangiogenic Effects of Commercial C-Reactive Protein on Various Human Endothelial Cell Types In Vitro: Implications of Contaminating Presence of Sodium Azide in Commercial Preparation , 2005, Circulation research.

[25]  C. Sabin,et al.  Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Giddings,et al.  C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[27]  L. Kuo,et al.  C-Reactive Protein Inhibits Endothelium-Dependent NO-Mediated Dilation in Coronary Arterioles by Activating p38 Kinase and NAD(P)H Oxidase , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[28]  P. Reitsma,et al.  Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans , 2005, Circulation research.

[29]  A. Hofman,et al.  Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.

[30]  J. Kemp,et al.  Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  J. Filep,et al.  Opposing Effects of C-Reactive Protein Isoforms on Shear-Induced Neutrophil-Platelet Adhesion and Neutrophil Aggregation in Whole Blood , 2004, Circulation.

[32]  D. Lang,et al.  C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial Preparations , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[33]  S. Devaraj,et al.  C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis? , 2004, Hypertension.

[34]  J. Filep,et al.  Conformational Rearrangement in C-Reactive Protein Is Required for Proinflammatory Actions on Human Endothelial Cells , 2004, Circulation.

[35]  Richard D. Weisel,et al.  C-Reactive Protein Upregulates Complement-Inhibitory Factors in Endothelial Cells , 2004, Circulation.

[36]  Lan Li,et al.  C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2004, Circulation.

[37]  C. Wanner,et al.  Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  E. Yeh,et al.  Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.

[39]  Hongwei Wang,et al.  Two-dimensional crystallization of rabbit C-reactive protein monomeric subunits. , 2003, Acta crystallographica. Section D, Biological crystallography.

[40]  S. Verma,et al.  C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle , 2003, Circulation.

[41]  Hitoshi Nishizawa,et al.  Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue , 2003, Circulation.

[42]  Edward T H Yeh,et al.  Coming of age of C-reactive protein: using inflammation markers in cardiology. , 2003, Circulation.

[43]  Yu-ling,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[44]  S. Devaraj,et al.  C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.

[45]  L. Lerman,et al.  C-Reactive Protein Relaxes Human Vessels In Vitro , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[46]  J. Filep,et al.  Loss of Pentameric Symmetry of C-reactive Protein Is Associated with Delayed Apoptosis of Human Neutrophils* , 2002, The Journal of Biological Chemistry.

[47]  J. Witztum,et al.  C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Sridevi Devaraj,et al.  Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.

[49]  N. Brot,et al.  I-PLA2 Activation during Apoptosis Promotes the Exposure of Membrane Lysophosphatidylcholine Leading to Binding by Natural Immunoglobulin M Antibodies and Complement Activation , 2002, The Journal of experimental medicine.

[50]  J. Borensztajn,et al.  Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. , 2002, The Biochemical journal.

[51]  C. Mold,et al.  Protection from Streptococcus pneumoniae Infection by C-Reactive Protein and Natural Antibody Requires Complement But Not Fcγ Receptors1 , 2002, The Journal of Immunology.

[52]  S. Barnum,et al.  Experimental Allergic Encephalomyelitis Is Inhibited in Transgenic Mice Expressing Human C-Reactive Protein1 , 2002, The Journal of Immunology.

[53]  J. Filep,et al.  Loss of Pentameric Symmetry of C-Reactive Protein Is Associated with Promotion of Neutrophil-Endothelial Cell Adhesion1 , 2001, The Journal of Immunology.

[54]  K. Kayaba,et al.  Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. , 2001, American journal of epidemiology.

[55]  J. Salmon,et al.  Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. , 2001, Arthritis and rheumatism.

[56]  V. Hombach,et al.  C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.

[57]  P. Mcgeer,et al.  Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.

[58]  J. Weiser,et al.  Expression of C-Reactive Protein in the Human Respiratory Tract , 2001, Infection and Immunity.

[59]  N. Brot,et al.  C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response , 2000, The Journal of experimental medicine.

[60]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[61]  J. Volanakis,et al.  Human C-Reactive Protein Is Protective against Fatal Salmonella enterica Serovar Typhimurium Infection in Transgenic Mice , 2000, Infection and Immunity.

[62]  Kai Simons,et al.  Lipid rafts and signal transduction , 2000, Nature Reviews Molecular Cell Biology.

[63]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[64]  J. Radosevich,et al.  Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. , 2000, The American journal of the medical sciences.

[65]  M. Pepys,et al.  C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction , 1999, The Journal of experimental medicine.

[66]  S. Bhakdi,et al.  Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[67]  C. Mold,et al.  Regulation of complement activation by C-reactive protein. , 1999, Immunopharmacology.

[68]  J. Kresl,et al.  Inhibition of Mouse Mammary Adenocarcinoma (EMT6) Growth and Metastases in Mice by a Modified Form of C-Reactive Protein , 1999, Tumor Biology.

[69]  L. Potempa,et al.  Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[70]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[71]  J. Filep,et al.  Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. , 1997, The Journal of clinical investigation.

[72]  D. Xia,et al.  Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[73]  A. Shrive,et al.  Structure solution of C-reactive proteins: molecular replacement with a twist. , 1996, Acta crystallographica. Section D, Biological crystallography.

[74]  J. Wright,et al.  Expression of C-reactive protein by alveolar macrophages. , 1996, Journal of immunology.

[75]  Dongxiao Zhang,et al.  STAT3 Participates in Transcriptional Activation of the C-reactive Protein Gene by Interleukin-6 (*) , 1996, The Journal of Biological Chemistry.

[76]  W. Liles,et al.  Glucocorticoids inhibit apoptosis of human neutrophils. , 1995, Blood.

[77]  J. Volanakis,et al.  Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. , 1995, Journal of immunology.

[78]  M. Pepys,et al.  The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. , 1994, The Journal of clinical investigation.

[79]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[80]  H. Tilg,et al.  Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells , 1993, The Journal of experimental medicine.

[81]  C. Haslett,et al.  Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators , 1993, Journal of leukocyte biology.

[82]  A. Mantovani,et al.  Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. , 1992, Blood.

[83]  G. Lozanski,et al.  Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.

[84]  Therese M. Murphy,et al.  Extrahepatic transcription of human C-reactive protein , 1991, The Journal of experimental medicine.

[85]  H. Gewurz,et al.  Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. , 1989, Journal of immunology.

[86]  H. Gewurz,et al.  Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes. , 1988, Cellular immunology.

[87]  H. Gewurz,et al.  Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. , 1988, Clinical immunology and immunopathology.

[88]  H. Gewurz,et al.  Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. , 1987, Molecular immunology.

[89]  L. Baum,et al.  Brief Definitive Report C-reactive Protein Is Produced by a Small Number of Normal Human Peripheral Blood Lymphocytes , 2022 .

[90]  J. Korenberg,et al.  Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. , 1985, The Journal of biological chemistry.

[91]  C. Vigo Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. , 1985, The Journal of biological chemistry.

[92]  H. Gewurz,et al.  Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. , 1983, Molecular immunology.

[93]  A. Feinstein,et al.  Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein , 1982, The Journal of experimental medicine.

[94]  J. Volanakis COMPLEMENT ACTIVATION BY C‐REACTIVE PROTEIN COMPLEXES * , 1982, Annals of the New York Academy of Sciences.

[95]  M. Pepys,et al.  Solid phase radioimmunoassays for human C-reactive protein. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[96]  K. Wirtz,et al.  Interaction of C-reactive protein with artificial phosphatidylcholine bilayers , 1979, Nature.

[97]  H. Gewurz,et al.  Interactions of C-reactive protein with the complement system. II. C- reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations , 1975, The Journal of experimental medicine.

[98]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.

[99]  M. H. Kaplan,et al.  Specificity of C-Reactive Protein for Choline Phosphate Residues of Pneumococcal C-Polysaccharide , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[100]  G. Moneta C-Reactive Protein-Bound Enzymatically Modified Low-Density Lipoprotein Does Not Transform Macrophages into Foam Cells , 2010 .

[101]  Jing Zhao,et al.  Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. , 2006, The international journal of biochemistry & cell biology.

[102]  Tarunendu Ghose Oswald Avery: the professor, DNA, and the Nobel Prize that eluded him. , 2004, Canadian bulletin of medical history = Bulletin canadien d'histoire de la medecine.

[103]  B. Haimovich,et al.  Phospholipase A2 enzymes regulate alpha IIb beta3-mediated, but not Fc gammaRII receptor-mediated, pp125FAK phosphorylation in platelets. , 1999, Thrombosis and haemostasis.

[104]  T. D. Du Clos The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. , 1996, Molecular biology reports.

[105]  M. Shields A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein , 1993, Immunologic research.

[106]  M. Pepys,et al.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. , 1983, Advances in immunology.

[107]  A. Feinstein,et al.  Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. , 1982, Immunology.

[108]  Peter Søgaard,et al.  Electromechanical Mapping for Detection of Myocardial Viability in Patients With Ischemic Cardiomyopathy , 2001, Circulation.